Look back at pharma news in week to July 27

29 July 2018

By Barbara Obstoj-Cardwell. Editor

Last week saw the surprise announcement from Gilead Sciences that both its chief executive and chairman are to leave the company. On the M&A front last week, Sangamo Therapeutics decision to acquire the small French biotech TxCell featured. Regulatory news included a US Food and Drug Administration approval for Agios rare cancer treatment Tibsovo, while an FDA advisory panel voted against approval of GlaxoSmithKline’s Nucala for COPD. Also disappointing, was the latest data on Biogen and Eisai’s Alzheimer’s candidate BAN2401.

Gilead: Full circle back to dominant HIV business as founders exit left

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK